Lower US sales of generic Revlimid dragged down second-quarter earnings, but double-digit growth in base markets and the upcoming relaunch of semaglutide offer near-term relief.
<iframe src="https://hindustansphere.com/embed/cluster/83037678a3c4b4bdc2aafa1d0fd76f38e7f77848" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Dr Reddy’s Q2 profit falls 36%, plans semaglutide relaunch in November"></iframe>
Lower US sales of generic Revlimid dragged down second-quarter earnings, but double-digit growth in base markets and the upcoming relaunch of semaglutide offer near-term relief.
